'Proove Biosciences has been recognized as a leader in personalized pain medicine and genetic testing, and uses evidence-based research to help physicians and patients better understand and treat their pain.' - Brian Meshkin, CEO, Proove Biosciences
Irvine, CA and Annapolis Junction, MD (PRWEB) July 28, 2014
Proove Biosciences, the commercial and research leader in personalized medicine, will be exhibiting data and research conducted through their latest proprietary testing services at this year’s International Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The event will take place July 30th-August 3rd, at the Hyatt Regency, in Orlando, Florida.
The meeting is designed to enhance the knowledge and clinical competence of physicians who care for patients suffering specificity from spine pain. The premier event will focus on the latest evidence-based findings, current research, and the future of the field.
“The International Spine Intervention Society is an industry leading organization dedicated to promoting the latest and most effective options for the treatment of pain from spine injury and disease,” stated Proove Biosciences CEO, Brian Meshkin. “Proove Biosciences has been recognized as a leader in personalized pain medicine and genetic testing, and uses evidence-based research to help physicians and patients better understand and treat their pain.”
Major components of this year’s forum will be emerging and alternative technologies in interventional spine care; how to prepare your practice in using outcome-based medicine and registries; and multiple research presentations.
“We are looking forward to exhibiting and explaining how our research is helping patients better manage and understand their pain, while lowering the associated healthcare costs and increasing prescription efficiency.”
About Proove Biosciences
Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.
Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).